A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy | MicrobiomeTrials← Back to trialsNCT06440967
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2024-07-31Est. Completion: 2026-06-25
Enrollment target: 982 participants Locations- Site CA15019, Sarnia, Ontario, Canada
- Site CA15016, Sault Ste. Marie, Ontario, Canada
- Site CA15002, Montreal, Quebec, Canada
- Site CA15001, Québec, Quebec, Canada
- Site CA15004, Québec, Quebec, Canada
- Site CA15003, Sherbrooke, Quebec, Canada
- Site CA15020, Victoriaville, Quebec, Canada
- Site CA15007, Trois-Rivières, Canada
- Site CZ42006, České Budějovice, Czechia
- Site CZ42003, Hořovice, Czechia
- Site CZ42002, Hradec Králové, Czechia
- Site CZ42011, Nový Jičín, Czechia
- Site CZ42001, Olomouc, Czechia
- Site CZ42005, Prague, Czechia
- Site CZ42008, Prague, Czechia
- Site CZ42013, Prague, Czechia
- Site CZ42004, Tábor, Czechia
- Site CZ42007, Vodňany, Czechia
- Site CZ42009, Vsetín, Czechia
- Site DK45007, Aalborg, Denmark
- Site DE45003, Esbjerg, Denmark
- Site DK45009, Hillerød, Denmark
Other microbiome trials you might be interested in
Vasomotor Symptoms Associated With MenopauseHealthy Volunteers
The purpose of this study is to evaluate the effects of single and multiple doses of ABCL635 administered by subcutaneou…
Calgary, CanadaEst. completion Feb 2027
Risk ReductionBreast Cancer
Women at risk for development of breast cancer and experiencing vasomotor menopausal symptoms (hot flashes) will be rand…
Duarte, United StatesEst. completion Oct 2026
Site DK45002, Næstved, DenmarkSite DE45008, Sønderborg, DenmarkSite FR33003, Angers, FranceSite FR33001, Bayonne, FranceSite FR33005, Bordeaux, FranceSite FR33018, Bordeaux, FranceSite FR33017, Caen, FranceSite FR33016, Dijon, FranceSite FR33013, Le Mans, FranceSite FR33007, Lille, FranceSite FR33012, Lyon, FranceSite FR33008, Montpellier, FranceSite FR33002, Saint-Herblain, FranceSite GR49005, Essen, North Rhine-Westphalia, GermanySite DE49001, Bottrop, GermanySite GR49013, Dresden, GermanySite DE49009, Leipzig, GermanySite DE49007, Mönchengladbach, GermanySite DE49010, München, GermanySite GR49003, Münster, GermanySite GR49014, Wolfsburg, GermanySite HU36008, Budapest, HungarySite HU36006, Debrecen, HungarySite HU36001, Eger, HungarySite HU36002, Kecskemét, HungarySite HU36010, Salgótarján, HungarySite HU36003, Székesfehérvár, HungarySite IT39011, Bologna, ItalySite IT39015, Genova, ItalySite IT39003, Milan, ItalySite IT39013, Mirano, ItalySite IT39017, Pavia, ItalySite IT39018, Reggio Emilia, ItalySite IT39012, Terni, ItalySite NL31010, Breda, NetherlandsSite NL31006, Dirksland, NetherlandsSite NL31001, Haarlem, NetherlandsSite NL31002, Rotterdam, NetherlandsSite NL31004, Rotterdam, NetherlandsSite NL31012, Rotterdam, NetherlandsSite NL31009, Terneuzen, NetherlandsSite PO48019, Poznan, Skorzewo, PolandSite PO48005, Bialystok, PolandSite PO48006, Bydgoszcz, PolandSite PO48004, Katowice, PolandSite PO48017, Katowice, PolandSite PO48015, Krakow, PolandSite PO48021, Krakow, PolandSite PO48007, Lodz, PolandSite PO48012, Lodz, PolandSite PO48002, Poznan, PolandSite PO48018, Poznan, PolandSite PO48010, Szczecin, PolandSite PO48003, Świdnik, PolandSite PO48001, Warsaw, PolandSite ES34011, Barcelona, SpainSite ES34020, Barcelona, SpainSite ES34010, Elche, SpainSite ES34003, Girona, SpainSite ES34005, Granada, SpainSite ES34006, Jaén, SpainSite ES34017, León, SpainSite ES34007, Madrid, SpainSite ES34019, Madrid, SpainSite ES34022, Madrid, SpainSite ES34023, Madrid, SpainSite ES34015, Majadahonda, SpainSite ES34002, Murcia, SpainSite ES34014, Murcia, SpainSite ES34008, Palma, SpainSite ES34025, Rivas-Vaciamadrid, SpainSite ES34009, Seville, SpainSite ES34024, Seville, SpainSite ES34013, Valencia, SpainSite GB44008, Bebington, Birkenhead, United KingdomSite GB44009, Guildford, Surrey, United KingdomSite GB44018, Aberdeen, United KingdomSite GB44019, Birmingham, United KingdomSite GB44003, Bristol, United KingdomSite GB44016, Cambridge, United KingdomSite GB44006, Glasgow, United KingdomSite GB44002, Liverpool, United KingdomSite GB44020, Liverpool, United KingdomSite GB44005, London, United KingdomSite GB44017, Oxford, United KingdomSite GB44001, Preston Lancashire, United KingdomSite GB44012, Redhill, United KingdomSite GB44010, Stroke on Trent, United KingdomRecruiting
Systemic Lupus Erythematosus (Sle)Primary Ovarian Insufficiency (Poi)
Background:
Systemic lupus erythematosus (SLE) is a disease that affects females nine times more often than males. Peop…
Bethesda, United StatesEst. completion May 31, 2027